|Bid||2.0700 x 1000|
|Ask||2.3900 x 1100|
|Day's Range||2.1100 - 2.4300|
|52 Week Range||1.8300 - 11.9500|
|Beta (5Y Monthly)||-1.59|
|PE Ratio (TTM)||N/A|
|Earnings Date||Apr 13, 2022 - Apr 18, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||9.99|
Working together on the world’s first treatment that targets the underlying causes of pyruvate kinase (“PK”) deficiency in children under the age of 18Expanded collaboration to include Phase 3 ACTIVATE-kids and ACTIVATE-kidsT studies CENTOGENE’s genetic testing and Biodatabank identify causative mutations, including the UGT1A1 and PKLR genes, and supports precise diagnosis CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, June 13, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the comme
Phreesia (PHR) delivered earnings and revenue surprises of 9.17% and 1.49%, respectively, for the quarter ended April 2022. Do the numbers hold clues to what lies ahead for the stock?
Change Healthcare (CHNG) delivered earnings and revenue surprises of -9.30% and 1.78%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?